Engineered Receptors Enable Soluble Ligand Detection and Programmable Cellular Therapies

SNIPRs, a Powerful New Therapeutic Approach

A new technology has been developed that has the potential to accelerate cures for cancer and autoimmune diseases. Synthetic Intramembrane Proteolysis Receptors (SNIPR) technology is a breakthrough platform that enables engineered cells to detect soluble ligands with unprecedented precision. Published in Nature (1), this work addresses a critical gap in cellular engineering by creating receptors capable of sensing naturally occurring and synthetic molecules—a capability that eluded earlier systems.

Background

Intra-cellular signaling pathways enable cells to produce, sense, and respond to external stimuli. Signaling is generally mediated by receptors with ligand specificity. Multiple Intracellular signaling pathways allow coordination of complex functions. This mechanism is essential in processes like oncogenesis and immune responses.
Engineering synthetic biological systems to interface with these signals could enhance therapies by directing precise cellular communication and coordination. Applications could target cancer, inflammation, and other diseases.

However, current technologies face limitations such as sensitivity, flexibility, and robustness. Overcoming these challenges is crucial for advancing cell-based therapeutic strategies.

The Problem

Despite advancements in molecular and cellular biology, receptors capable of responding robustly to soluble ligands remain limited. Cancer and inflammatory diseases need new ways to therapeutically target these pathways. Existing approaches, such as CAR T cells, have demonstrated potential but often rely on complex, multi-component systems, limiting their translational applications.

A Solution: Cellular Signaling by SNIPRs

SNIPRs demonstrated remarkable versatility by sensing both physiological and synthetic ligands. Chimeric receptors are engineered by researchers to have antigen specific antibody fragments (single-chain variable fragments: scFvs) that recognize soluble receptor ligands, such as cytokines and growth factors. Unlike other recent technologies, SNIPRs employ an endocytosis-dependent pathway. When soluble ligands such as TGF-β or VEGF bind to SNIPRs, the receptor-ligand complex undergoes internalization into acidic endosomes. Here, pH-dependent proteolytic cleavage by γ-secretase releases a transcription factor, which migrates to the nucleus to activate downstream genes.

Tunable Sensitivity to Natural and Synthetic Ligands

Scientists engineered receptors to recognize TGF-β, VEGF, FGF2, and IFN-γ, and transduced them into primary human T cells, which then gave robust ligand specific activation with minimal baseline activity. For example, TGF-β SNIPRs achieved a 40-fold induction of reporter genes upon ligand exposure, surpassing the performance of earlier technologies. Notably, SNIPRs could distinguish between two different forms of TGF-β, active and latent. This is particularly important because the active form of TGF-β drives immunosuppression in tumor microenvironments.
One of the many advantages of SNIPRs is the ability to enable bio-orthogonal communication within cells. Bio-orthangonal refers to molecular interactions that can occur inside cells without interfering with natural biochemical processes. Scientists designed “OrthoSNIPRs” using computationally engineered signaling channels impervious to natural cytokines. By varying ligand valency and geometry, researchers fine-tuned receptor-ligand activation thresholds, achieving superior sensitivity over a native response. Such programmability allows synthetically engineered cellular responses to process combinatorial inputs, mimicking natural systems.

SNIPR Enhancement of CAR-T Cellular Therapy, Localized Antitumor Activity and Reduced Toxicity

A landmark application of SNIPRs is their integration with CAR T-cell therapies to mitigate on-target, off-tumor toxicity. In mouse xenograft models, SNIPR-CAR T cells were activated only in the presence of the appropriate tumor-derived soluble factors like TGF-β or VEGF. This approach eliminated lethal weight loss observed with constitutive CARs, which attacked healthy tissues expressing low antigen levels. For instance, in lung adenocarcinoma models, SNIPR-CAR T cells suppressed tumor growth without systemic toxicity, whereas conventional CARs caused fatal cytokine release syndrome.

The platform’s safety was further enhanced through “dimerSNIPRs,” where chemical inducers triggered receptor clustering and activation independently of ligands (2). This feature enables remote control over therapeutic cells, akin to the SNIP-CAR system developed by Labaneih et al. (3), which uses FDA-approved protease inhibitors to regulate CAR activity.

Building Synthetic Signaling Pathways with Orthogonal Communication

SNIPRs unlock the potential for engineered cells to form synthetic signaling pathways. By pairing OrthoSNIPRs with secreted ligands, the study demonstrated intercellular communication between “sender” and “receiver” cells, offering superior modularity compared to other contemporary technologies.

Such systems could coordinate multicellular behaviors, such as self-limiting cytokine production or feedback-controlled tumor infiltration. In one proof-of-concept, OrthoSNIPRs were combined with ligands that are designed to enhance endocytosis, amplifying signal strength by 300%. These tools may revolutionize tissue engineering, enabling spatial ligand gradients to regenerate damaged tissues.

Potential Applications and Future Directions, Precision Cancer Immunotherapy

SNIPR-CAR T cells could overcome the toxicity barriers plaguing solid tumor therapies. By restricting CAR expression to tumor sites, SNIPRs prevent off-target damage to healthy tissues expressing antigens like HER2 or mesothelin. This approach is being advanced clinically via platforms like SNIP-CARs, which use small-molecule regulators to toggle T-cell activity.

Autoimmune and Inflammatory Disease

OrthoSNIPRs could deliver anti-inflammatory payloads (e.g., IL-10) exclusively to disease sites. As proof of concept another technology targeting a CNS-specific protein recently alleviated neuroinflammation in multiple sclerosis models, suggesting SNIPRs might achieve similar efficacy with enhanced specificity.

Conclusion

The SNIPR platform represents a paradigm shift in cell therapy, merging the precision of receptor signaling with the flexibility of soluble ligand detection. SNIPRs open avenues for safer immunotherapies, synthetic signaling pathways and programmable tissue engineering. Future work may focus on enhancing SNIPR sensitivity, integrating multi-input signals, and minimizing immunogenicity for clinical translation. As the field progresses, SNIPRs will likely serve as foundational tools in the next generation of cellular medicines.

Citations

  1. Piraner et al. Engineered receptors for soluble cellular communication and disease sensing.
    Nature 638:805, 2025. DOI: 10.1038/s41586-024-08366-0
  2. Zhou, X. et al. Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Molecular Therapy 4:823, 2016.
  3. Labanieh, L. et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors.
    Cell 185:1745, 2022.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)